We address strategic cognitive sequencing, the "outer loop" of human cognition: how the brain decides what cognitive process to apply at a given moment to solve complex, multistep cognitive tasks. We argue that this topic has been neglected relative to its importance for systematic reasons but that recent work on how individual brain systems accomplish their computations has set the stage for productively addressing how brain regions coordinate over time to accomplish our most impressive thinking. We present four preliminary neural network models. The first addresses how the prefrontal cortex (PFC) and basal ganglia (BG) cooperate to perform trial-and-error learning of short sequences; the next, how several areas of PFC learn to make predictions of likely reward, and how this contributes to the BG making decisions at the level of strategies. The third models address how PFC, BG, parietal cortex, and hippocampus can work together to memorize sequences of cognitive actions from instruction (or "self-instruction"). The last shows how a constraint satisfaction process can find useful plans. The PFC maintains current and goal states and associates from both of these to find a "bridging" state, an abstract plan. We discuss how these processes could work together to produce strategic cognitive sequencing and discuss future directions in this area.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3722785 | PMC |
http://dx.doi.org/10.1155/2013/149329 | DOI Listing |
Digit Health
October 2024
Department of Psychiatry, Faculty of Medicine, Universiti Kebangsaan Malaysia, Kuala Lumpur, Malaysia.
Background: Mental health care during the postpartum period is notably underexplored within Asian demographics, with barriers such as stigma, privacy concerns, logistical challenges, and a shortage of mental health professionals that limits access to optimal mental healthcare. Previous studies found that mobile health (mHealth) technology has been offering a promising solution to these issues. However, the perspectives of mothers on existing mental health services and their mHealth needs are still not well understood and warrant further exploration.
View Article and Find Full Text PDFNat Commun
January 2025
Department of Clinical and Experimental Epilepsy, Queen Square Institute of Neurology, UCL, London, WC1N 3BG, UK.
Approximately 40% of individuals undergoing anterior temporal lobe resection for temporal lobe epilepsy experience episodic memory decline. There has been a focus on early memory network changes; longer-term plasticity and its impact on memory function are unclear. Our study investigates neural mechanisms of memory recovery and network plasticity over nearly a decade post-surgery.
View Article and Find Full Text PDFBehav Brain Sci
January 2025
CNRS-IKER (UMR 5478), Bayonne, France.
The article provides an important warning but its general conclusions should be nuanced: (i) When there is no evidence for it, we should depart from the hypothesis that a species lacks a particular cognitive capacity, and (ii) inferences from absence of evidence can be epistemically sound and scientifically strategic in cognitive and linguistic archaeology.
View Article and Find Full Text PDFGenes Brain Behav
February 2025
Département de Readaptation et gériatrie, University of Geneva, Geneva, Switzerland.
Human microbiota-associated murine models, using fecal microbiota transplantation (FMT) from human donors, help explore the microbiome's role in diseases like Alzheimer's disease (AD). This study examines how gut bacteria from donors with protective factors against AD influence behavior and brain pathology in an AD mouse model. Female 3xTgAD mice received weekly FMT for 2 months from (i) an 80-year-old AD patient (AD-FMT), (ii) a cognitively healthy 73-year-old with the protective APOEe2 allele (APOEe2-FMT), (iii) a 22-year-old healthy donor (Young-FMT), and (iv) untreated mice (Mice-FMT).
View Article and Find Full Text PDFJ Prev Alzheimers Dis
January 2025
Alzheimer's Drug Discovery Foundation, New York, NY, USA. Electronic address:
There is growing consensus in the Alzheimer's community that combination therapy will be needed to maximize therapeutic benefits through the course of the disease. However, combination therapy raises complex questions and decisions for study sponsors, from preclinical research through clinical trial design to regulatory, statistical, and operational considerations. In January 2024, the Alzheimer's Drug Discovery Foundation convened an expert advisory board to discuss the key considerations in each of these areas.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!